NCT07784270ClinicalTrials.gov
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)
In brief
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Phase 31,500 participants sought230 sites16 countries
Categories
Registered in 1 registry
- ClinicalTrials.govNCT07784270Open this record at ClinicalTrials.govSynced 3 weeks ago
One study can be registered in several registries. We show it once and link every record we hold.
Trial information is shown as published by the registry, in its original language.
Interested in this study?
Sign in or create an account to register your interest and follow this study.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Not stated: Registered after enrolment began (about 5 days after the recorded start)First posted 2026-08-25; recorded start 2026-08-20
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 2 conditions.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 218 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study, international in scope: 1,500 participants (target), run at 230 sites, across 16 countries.
How this score is built
- Enrolment32/40
1,500 participants (target)
- Site count25/25
218 sites
- Country count15/15
16 countries
- Planned duration7/10
Planned over about 24 months
- Sponsor scale10/10
AstraZeneca has led 1,017 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Summary
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Conditions
- Obesity or Overweight
- Diabetes Mellitus, Type 2
Eligibility
| Sex | All |
|---|---|
| Ages | 18 Years – No maximum |
| Healthy volunteers | No |
Eligibility as written in the registry
Eligibility in plain statements
This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.
Study design
| Study type | Interventional |
|---|---|
| Phase | Phase 3 |
| Allocation | Randomised |
| Intervention model | PARALLEL |
| Primary purpose | TREATMENT |
| Masking | QUADRUPLE (4) |
| Enrolment | 1,500 participants sought |
Sponsor and collaborators
- AstraZeneca Sponsor
Arms and interventions
- AZD6234 Dose 1EXPERIMENTAL
AZD6234 Dose 1
- AZD6234 Dose 2EXPERIMENTAL
AZD6234 Dose 2
- PlaceboPLACEBO_COMPARATOR
Matching placebo
Interventions
- Drug Lenbelintide
IMP injected subcutaneously, once a week. Unit dose strength as per CSP.
- Drug Placebo
Placebo matching IMP dose injected subcutaneously, once a week.
Outcome measures
Primary outcome
Percent change in body weight from baseline at 68 weeks of treatment.
To evaluate the effect of AZD6234 compared to placebo in percent body weight change
Time frame 68 weeks
Secondary outcome
Absolute change in weight (kg) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo on absolute change in weight
Time frame 68 weeks
Secondary outcome
Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo in body weight loss of at least 5%
Time frame 68 weeks
Secondary outcome
Achievement of at least 10 % body weight loss from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo in body weight loss of at least 10%
Time frame 68 weeks
Secondary outcome
Change in haemoglobin A1C from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 on haemoglobin A1C change
Time frame 68 weeks
Secondary outcome
Change in waist circumference (cm) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo on waist circumference change
Time frame 68 weeks
Secondary outcome
Percent change in triglycerides from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo on triglycerides percent change
Time frame 68 weeks
Secondary outcome
Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo on systolic blood pressure change
Time frame 68 weeks
Secondary outcome
Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset
Body Composition Sub-study: To evaluate the effect of AZD6234 compared to placebo on body composition change in the DXA subset of participants
Time frame 68 weeks
Dates
| Start date | August 20, 2026 (actual) |
|---|---|
| Primary completion | August 9, 2028 (estimated) |
| Completion | August 9, 2028 (estimated) |
| First posted | August 25, 2026 (actual) |
| Last updated | October 28, 2026 |
| Results posted | Not stated in the registry record |
| Status last verified | October 2026 |
Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.
Locations
58 sites are recruiting
Argentina
| Facility | City | State or region | Status |
|---|---|---|---|
| Research Site | Buenos Aires | Recruiting | |
| Research Site | CABA | Recruiting | |
| Research Site | Ciudad de Buenos Aires | Recruiting | |
| Research Site | Mendoza | Recruiting | |
| Research Site | Ramos Mejía | Not yet recruiting | |
| Research Site | Rosario | Recruiting | |
| Research Site | San Nicolás | Not yet recruiting |
Australia
| Facility | City | State or region | Status |
|---|---|---|---|
| Research Site | Botany | Recruiting | |
| Research Site | Camberwell | Recruiting | |
| Research Site | Charlestown | Recruiting | |
| Research Site | Helensvale | Recruiting | |
| Research Site | Maroubra | Recruiting | |
| Research Site | Waitara | Recruiting |
Canada
| Facility | City | State or region | Status |
|---|---|---|---|
| Research Site | Calgary | Alberta | Recruiting |
| Research Site | Hamilton | Ontario | Recruiting |
| Research Site | Joliette | Quebec | Recruiting |
| Research Site | Markham | Ontario | Recruiting |
| Research Site | Moncton | New Brunswick | Recruiting |
| Research Site | Montreal | Quebec | Recruiting |
| Research Site | Montreal | Quebec | Recruiting |
| Research Site | North York | Ontario | Recruiting |
| Research Site | Québec | Quebec | Recruiting |
| Research Site | Sarnia | Ontario | Recruiting |
| Research Site | Scarborough Village | Ontario | Recruiting |
| Research Site | Stoney Creek | Ontario | Withdrawn |
| Research Site | Stouffville | Ontario | Recruiting |
| Research Site | Toronto | Ontario | Recruiting |
| Research Site | Toronto | Ontario | Recruiting |
| Research Site | Trois-Rivières | Quebec | Recruiting |
| Research Site | Truro | Nova Scotia | Recruiting |
| Research Site | Vancouver | British Columbia | Recruiting |
Chile
| Facility | City | State or region | Status |
|---|---|---|---|
| Research Site | Concepción | Not yet recruiting | |
| Research Site | Concepción | Not yet recruiting | |
| Research Site | Concepción | Not yet recruiting | |
| Research Site | Iquique | Not yet recruiting | |
| Research Site | Las Condes | Not yet recruiting | |
| Research Site | Providencia | Not yet recruiting | |
| Research Site | Santiago | Not yet recruiting | |
| Research Site | Santiago | Not yet recruiting | |
| Research Site | Santiago | Not yet recruiting |
China
| Facility | City | State or region | Status |
|---|---|---|---|
| Research Site | Beijing | Not yet recruiting | |
| Research Site | Cangzhou | Not yet recruiting | |
| Research Site | Changchun | Not yet recruiting | |
| Research Site | Chengdu | Not yet recruiting | |
| Research Site | Chengdu | Not yet recruiting | |
| Research Site | Danyang | Not yet recruiting | |
| Research Site | Ganzhou | Not yet recruiting | |
| Research Site | Guangzhou | Not yet recruiting | |
| Research Site | Huizhou | Not yet recruiting | |
| Research Site | Huzhou | Not yet recruiting |
180 further sites are listed in the registry record.
Study documents
No documents are linked in this registry record.
Changes over time
- October 28, 2026
Completion date moved later
Primary completion delayed 1 days
2028-08-082028-08-09
- October 28, 2026
Site added
3 sites added (230 total)
227230
- September 22, 2026
Status changed
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- September 22, 2026
Recruitment opened
Recruitment opened
NOT_YET_RECRUITINGRECRUITING
- September 22, 2026
Completion date moved earlier
Primary completion advanced 1 days
2028-08-092028-08-08
- September 22, 2026
Site added
9 sites added (227 total)
218227